April 17, 2018

Scott C. Brun, MD

Vice President, Corporate Strategy Office and Head of AbbVie Ventures
Scott Brun, M.D., is AbbVie’s Vice President, Chief Strategy Office and Head of AbbVie Ventures, where he works closely with the Chief Strategy Officer and executive management team to identify and execute on strategic venture investments that are closely aligned with AbbVie’s overall R&D and corporate strategy. Scott also serves as AbbVie’s Vice President, Scientific Affairs.

Prior to this role, Scott led Pharmaceutical Development at AbbVie and was responsible for advancing a broad pipeline across several therapeutic areas. In his 20+ year career at Abbott/AbbVie, he held roles of increasing responsibility across the research and development organization.

Scott earned his bachelor’s degree in biochemistry from the University of Illinois at Urbana-Champaign. He earned his medical degree from The Johns Hopkins University School of Medicine and completed ophthalmology training at the Massachusetts Eye and Ear Infirmary/Harvard Medical School.

Thomas Hudson, MD

Vice President, Head of Oncology Discovery and Early Development
Thomas Hudson, M.D., is AbbVie’s Vice President, Head of Oncology Discovery and Early Development, and is based in Redwood City, California.

Prior to his time at AbbVie, he was the President and Scientific Director of the Ontario Institute for Cancer Research, where he led the institute’s work in translational research for the prevention, detection, diagnosis and treatment of cancer.

Internationally renowned for his work in genomics and human genome variation, his past positions include leadership roles as Founder and Director of the McGill University and Genome Quebec Innovation Centre and Assistant Director of the Whitehead/MIT Center for Genome Research. Dr. Hudson has served as a scientific advisor to many public organizations, including Genome England, the National Human Genome Research Institute (NIH) and the STARR Cancer Foundation.

KT Moortgat, PhD

Director, AbbVie Ventures
KT Moortgat, Ph.D., joined AbbVie Ventures in 2017 to build the west coast investment efforts. She is an enabler of technology translation, through startup incubation, investment, and partnering.

Prior to joining AbbVie, she was CEO of a microbiome therapeutics company through the funding and launch of a multi-site Phase 2b study of its lead product candidate, and held other leadership positions in venture-backed life science companies.

Previously, KT was a partner at the venture capital firm Mohr Davidow Ventures (MDV) for six years. She also founded and led the hub of entrepreneurship at QB3 and the University of California San Francisco. KT earned her bachelor’s degree from University of California, Berkeley. She earned her doctorate degree at the Salk Institute.